Less-Intensive AML Treatment Increased Transplant Success
Patients receiving a combination regimen achieved higher rates of stem cell transplant than those on standard chemotherapy.
Updated on Oct. 12, 2026 in Cancer
Live Poll
Would you prioritize treatment quality of life over potential survival length in a medical situation?
A combination of azacitidine and venetoclax extended median event-free survival for acute myeloid leukemia (AML) patients to 14.5 months compared to 6.2 months with induction chemotherapy. This less-intensive regimen may help more patients reach a potentially curative stem cell transplant.
Why it matters
The regimen is better tolerated and leads to fewer or shorter hospitalizations for patients, 72% of whom had adverse-risk disease. This shift potentially improves quality of life and outcomes for those struggling to access or complete more aggressive chemotherapy.
In a study of AML patients, 72% of whom had adverse-risk disease, the combination of azacitidine and venetoclax significantly improved event-free survival compared to standard induction chemotherapy. The results suggest this approach is a viable alternative, though overall survival remained similar.
The players
Amir Fathi
A researcher who studies clinical outcomes and believes future phase 3 trials may shift focus away from overall survival as a primary end point.
The details
The treatment utilizes azacitidine and venetoclax, a less-intensive regimen than standard induction chemotherapy. This combination helps patients manage side effects more effectively, leading to lower 30-day and 60-day mortality. By improving tolerance and patient response, the regimen acts as a bridge, allowing a greater proportion of individuals to become candidates for a life-saving stem cell transplant.
Timeline
Lower 30-day mortality occurred with the less-intensive regimen.
Lower 60-day mortality occurred with the less-intensive regimen.
Health Landscape
This development reflects an ongoing shift in clinical oncology trials for AML, where researchers are moving toward prioritizing transplant accessibility and patient tolerance. The findings challenge the reliance on traditional overall survival as the sole benchmark for treatment success.
If you or a loved one are navigating an AML diagnosis, talk to your oncologist about whether less-intensive induction options might improve your eligibility for a stem cell transplant. Discuss the potential benefits of improved tolerance versus traditional intensive chemotherapy regimens.
The takeaway
Less-intensive regimens like azacitidine-venetoclax may be a powerful tool for improving transplant rates in high-risk patients. Continue to track updates in clinical trial end points, as these metrics significantly influence which treatments become the new standard of care.
Further reading
For more information on current treatment trends, visit the Cancer section of our site.
Source note: This article includes information reported by Ajmc.
Live Poll
Would you prioritize treatment quality of life over potential survival length in a medical situation?
